AstrocytomaSymptoms, Doctors, Treatments, Advances & More
Astrocytoma Overview
Learn About Astrocytoma
View Main Condition: Brain Tumor
Duke Cancer Center Brain Tumor Clinic
Henry Friedman is a Neurosurgery specialist and a Hematologist practicing medicine in Durham, North Carolina. Dr. Friedman is rated as an Elite provider by MediFind in the treatment of Astrocytoma. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, and Brain Tumor. Dr. Friedman is board certified in American Board Of Pediatrics, General Pediatrics and American Board Of Pediatrics, Pediatric Hematology-Oncology. Dr. Friedman is currently accepting new patients.
Ricardo Komotar is an Oncologist and a Neurosurgery provider practicing medicine in Miami, Florida. Dr. Komotar is rated as an Elite provider by MediFind in the treatment of Astrocytoma. He is also highly rated in 57 other conditions, according to our data. His clinical expertise encompasses Brain Tumor, Meningioma, Glioblastoma, Awake Craniotomy, and Posterior Fossa Decompression. Dr. Komotar is currently accepting new patients.
Duke Cancer Center Brain Tumor Clinic
Allan Friedman is a Neurosurgery provider practicing medicine in Durham, North Carolina. Dr. Friedman is rated as an Elite provider by MediFind in the treatment of Astrocytoma. He is also highly rated in 43 other conditions, according to our data. His clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, Awake Craniotomy, and Laminectomy. Dr. Friedman is board certified in American Board Of Neurological Surgery, Neurological Surgery. Dr. Friedman is currently accepting new patients.
Summary: The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma is thus limited due to t...
Summary: The objective of this study is to evaluate the safety, tolerability, efficacy profile, and effect on growth and development of vorasidenib in pediatric participants aged 12 to \< 18 years old with grade 2 glioma with an IDH1 or IDH2 mutation. The study includes a screening period, a treatment period consisting of continuous 28-day cycles of treatment, a safety follow-up period and a long-term foll...

Keep Punching supports patients, healthcare providers, and researchers in their fight to prevent and eradicate brain cancer and minimize treatment-related side effects that may adversely impact function and comfort.


